Description

ZOPISIGN 7.5 TABLET is a powerful, fast-acting sleep aid used in the short-term treatment of insomnia. It contains Zopiclone 7.5 mg, a non-benzodiazepine hypnotic that acts on the brain’s GABA receptors to promote relaxation and sleep onset. Designed for those struggling with difficulty falling asleep, nighttime awakenings, or early morning arousals, ZOPISIGN enhances sleep duration and quality without significantly altering natural sleep patterns.

Its sedative effect begins within 30 minutes of intake, ensuring a restful sleep lasting 6 to 8 hours. Due to its reliable efficacy and fast onset, ZOPISIGN is recommended for adults suffering from transient, situational, or short-term insomnia.

Manufactured and globally distributed by BLUEPILL EXPRESS, a trusted name in international pharmaceutical export and third-party manufacturing, ZOPISIGN 7.5 TABLET is produced in WHO-GMP, ISO, and FDA-compliant facilities to meet global standards of safety, efficacy, and consistency. BLUEPILL EXPRESS delivers to markets across Asia, Africa, Europe, the CIS, Latin America, and the Middle East, supporting pharmaceutical partners with custom packaging, regulatory documentation, and private labeling.

• Non-benzodiazepine hypnotic (Cyclopyrrolone derivative)

• Central nervous system (CNS) depressant

Zopiclone enhances the effect of GABA, the brain’s primary inhibitory neurotransmitter, by binding to GABA-A receptors. This results in sedation, reduction in sleep latency, and improved sleep maintenance—without significantly disrupting REM or deep sleep stages.

• Short-term insomnia

• Trouble falling asleep or maintaining sleep

• Sleep disturbances due to stress, anxiety, or travel

• Situational or lifestyle-induced insomnia

• Fast onset of action—induces sleep in about 30 minutes

• Promotes restful, uninterrupted sleep for up to 8 hours

• Improves overall sleep quality and efficiency

• Lower risk of dependence than traditional benzodiazepines (when used short-term)

• Manufactured and exported by BLUEPILL EXPRESS under global quality certifications

• Recommended adult dose: One tablet (7.5 mg) taken orally at bedtime

• Ensure a minimum of 7–8 hours of sleep opportunity after dosing

• Not intended for continuous long-term use (recommended for 7–10 days maximum)

• Avoid use with alcohol or other CNS depressants

• Not suitable for pediatric use

• Use with caution in elderly patients or those with liver/respiratory conditions

• Risk of dependence, tolerance, or withdrawal with prolonged use

• May impair alertness; avoid driving or operating machinery after use

• Avoid alcohol during treatment

• Metallic or bitter aftertaste

• Daytime drowsiness or dizziness

• Headache

• Dry mouth

• Gastrointestinal discomfort

• In rare cases: confusion, hallucinations, or parasomnia (e.g., sleepwalking)

Seek medical guidance if any severe or unusual side effects occur.

BLUEPILL EXPRESS stands as a leading global third-party pharmaceutical manufacturer and exporter, delivering high-quality medicines that meet international regulatory and safety standards. From bulk production to customized formulations and global export logistics, our operations are designed to serve pharmacies, hospitals, importers, and distributors worldwide.

ZOPISIGN 7.5 TABLET is part of BLUEPILL EXPRESS’s extensive CNS and neuropsychiatric product line, trusted by healthcare providers for effective sleep management solutions. We provide custom labeling, export documentation, and private brand support to meet your business needs in both regulated and semi-regulated markets.